Pfizer's buyback line remains useful because it is empty. The paper's May 11 article on Pfizer's zero-buyback quarter placed the company beside Apple and Berkshire as the restrained side of capital return week.

The SEC exhibit says first-quarter revenue was $14.5 billion, up 5 percent year over year and 2 percent operationally, while Pfizer reaffirmed full-year guidance of $59.5 billion to $62.5 billion in revenue and adjusted diluted EPS of $2.80 to $3.00. [1]

The capital-allocation paragraph is the point. Pfizer returned $2.4 billion through dividends in the first three months, said no share repurchases had been completed in 2026, and stated that current guidance assumes no share repurchases this year. It also says buybacks may resume only after the balance sheet is delevered. [1]

The drug story gives management cover. Pfizer said launched and acquired products grew 22 percent operationally and highlighted Padcev, Eliquis, oncology biosimilars, Nurtec and Lorbrena as growth contributors. [1] If those products keep carrying the quarter, the absence of buybacks looks deliberate. If they stall, restraint will look like necessity.

MSM can call that conservative. X can call it a lack of confidence. The cleaner reading is that Pfizer has left investors a measurable promise: if repurchases return before deleveraging, discipline was marketing; if not, the dividend and pipeline must do the work.

-- THEO KAPLAN, San Francisco